Evotec unveiled a multi‑year restructuring that includes eliminating up to 800 positions—roughly one‑sixth of its workforce—and closing four facilities as it streamlines operations under a plan dubbed 'Horizons.' The company will consolidate scientific expertise into new Centers of Excellence and retain key hubs for biologics and process engineering but will shutter sites including Abingdon (UK), Framingham (MA), Lyon and Munich. Management said the measures will reduce costs and sharpen focus on higher‑value discovery and preclinical segments and on its biologics subsidiary Just‑Evotec Biologics (JEB). Customers and partners will watch the transition closely for potential service disruptions in CDMO and discovery services amid an already tight market for specialized manufacturing capacity.